Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XY03-EA in Acute Ischemic Stroke
NCT06755944Phase 2Completed
- Sponsor
- Yiling Pharmaceutical
- Start
- Dec 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of XY03-EA in ischemic stroke, sponsored by Yiling Pharmaceutical. Started Dec 2024; status: completed.
02
Drugs
XY03-EA
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06755944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06755944.